138 related articles for article (PubMed ID: 33993033)
1. Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches.
Lonie JM; Barbour AP; Dolcetti R
Cancer Treat Rev; 2021 Jul; 98():102219. PubMed ID: 33993033
[TBL] [Abstract][Full Text] [Related]
2. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
Milano F; Jorritsma T; Rygiel AM; Bergman JJ; Sondermeijer C; Ten Brinke A; vanHam SM; Krishnadath KK
Scand J Immunol; 2008 Dec; 68(6):616-23. PubMed ID: 19055699
[TBL] [Abstract][Full Text] [Related]
3. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.
Gotovac JR; Liu DS; Yates MJ; Milne JV; Macpherson AA; Simpson KJ; Eslick GD; Mitchell C; Duong CP; Phillips WA; Clemons NJ
J Pathol; 2020 Nov; 252(3):317-329. PubMed ID: 32737994
[TBL] [Abstract][Full Text] [Related]
4. Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma.
Belle CJ; Lonie JM; Brosda S; Barbour AP
Front Immunol; 2023; 14():1330635. PubMed ID: 38155973
[TBL] [Abstract][Full Text] [Related]
5. Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.
Buckley AM; Dunne MR; Morrissey ME; Kennedy SA; Nolan A; Davern M; Foley EK; Clarke N; Lysaght J; Ravi N; O'Toole D; MacCarthy F; Reynolds JV; Kennedy BN; O'Sullivan J
Sci Rep; 2020 Jul; 10(1):12105. PubMed ID: 32694701
[TBL] [Abstract][Full Text] [Related]
6. Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS.
Guo N; Minas G; Synowsky SA; Dunne MR; Ahmed H; McShane R; Bhardwaj A; Donlon NE; Lorton C; O'Sullivan J; Reynolds JV; Caie PD; Shirran SL; Lynch AG; Stewart AJ; Arya S
J Proteomics; 2022 Aug; 266():104684. PubMed ID: 35842220
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens.
Milano F; Krishnadath KK
Hum Immunol; 2008 Oct; 69(10):614-24. PubMed ID: 18703104
[TBL] [Abstract][Full Text] [Related]
8. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
9. The intra-class heterogeneity of immunophenotyping and immune landscape in oesophageal cancer and clinical implications.
Xie Y; Shi X; Chen Y; Wu B; Gong X; Lu W; Lin W
Ann Med; 2021 Dec; 53(1):626-638. PubMed ID: 33860722
[TBL] [Abstract][Full Text] [Related]
10. Preclinical models of esophageal adenocarcinoma for drug development.
Liu DS; Duong CP; Phillips WA; Clemons NJ
Discov Med; 2016 Dec; 22(123):371-379. PubMed ID: 28147219
[TBL] [Abstract][Full Text] [Related]
11. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
Bockorny B; Pectasides E
Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Jones JO; Smyth EC
Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
[TBL] [Abstract][Full Text] [Related]
14. Impact of Deoxycholic Acid on Oesophageal Adenocarcinoma Invasion: Effect on Matrix Metalloproteinases.
Quilty F; Byrne AM; Aird J; El Mashad S; Parra-Blanco A; Long A; Gilmer JF; Medina C
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126685
[TBL] [Abstract][Full Text] [Related]
15. Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma.
McShane R; Arya S; Stewart AJ; Caie PD; Bates M
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188598. PubMed ID: 34332022
[TBL] [Abstract][Full Text] [Related]
16. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma.
Melo AM; O'Brien AM; Phelan JJ; Kennedy SA; Wood NAW; Veerapen N; Besra GS; Clarke NE; Foley EK; Ravi A; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; Conroy MJ; Hogan AE; O'Sullivan J; Dunne MR
Front Immunol; 2019; 10():1580. PubMed ID: 31354725
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?
Lee S; Cohen DJ
Expert Opin Pharmacother; 2019 Feb; 20(3):357-366. PubMed ID: 30526127
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
19. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
[TBL] [Abstract][Full Text] [Related]
20. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.
Allott EH; Lysaght J; Cathcart MC; Donohoe CL; Cummins R; McGarrigle SA; Kay E; Reynolds JV; Pidgeon GP
Mol Carcinog; 2013 Feb; 52(2):144-54. PubMed ID: 22121096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
